ACACIA RESEARCH CORP (ACTG): M&A transaction — Acacia Research sells entire Arix stake for $57.1M to RTW Biotech

ACACIA RESEARCH CORP

Sold 33,023,210 Arix shares for $57,078,670 aggregate (~£1.43/share).
Buyer: RTW Biotech Opportunities Operating Ltd, a subsidiary of RTW Biotech Opportunities Ltd.
Transaction closed January 19, 2024; Acacia no longer owns any Arix shares.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.99

ACACIA RESEARCH CORP completed a disposition involving RTW Biotech Opportunities Operating Ltd for US$57,078,670.12 in aggregate (representing £1.43 per share at an exchange rate of 1.2087 USD/GBP) (closed 2024-01-19).

Action: disposition
Counterparty: RTW Biotech Opportunities Operating Ltd
Consideration: US$57,078,670.12 in aggregate (representing £1.43 per share at an exchange rate of 1.2087 USD/GBP)
Closing: 2024-01-19

Exact text from the filing

On January 19, 2024, Acacia Research Corporation (the “Company”) completed the sale of its 33,023,210 shares of Arix Bioscience PLC (“Arix”) to RTW Biotech Opportunities Operating Ltd, a subsidiary of RTW Biotech Opportunities Limited, for US$57,078,670.12 in aggregate (representing £1.43 per share at an exchange rate of 1.2087 USD/GBP).

View on SEC.gov

31 m&a transactions filed in the last 30 days. Browse all m&a transactions →

ACACIA RESEARCH CORP filing history →

Source: SEC EDGAR

accession 0000934549-24-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.